Roflumilast: a guide to its use in chronic obstructive pulmonary disease
Drugs & Therapy Perspectives, 08/08/2011
Roflumilast is the first selective phosphodiesterase 4 inhibitor indicated to treat severe chronic obstructive pulmonary disease associated with chronic bronchitis in patients with a history of frequent exacerbations. It significantly improves lung function and exacerbation rates, and has an acceptable tolerability profile in this patient population.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.